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Summary: In pätients who had undergone orthotopic liver transplantation, malabsorption of prednisolone
or increased metabolism of prednisolone was suspected. In order to rule out this possibility, urinary
prednisolone, and some of its metabolites, viz prednisone and 6 ß-hydroxyprednisolone, were determined by
means of a gas Chromatographie assay. To evaluate this assay aliquots of a pooled urine from several of our
pätients were analysed in multiplicate (n = 10). Mean prednisone, prednisolone and 6 ß-hydroxyprednisolone
concentrations of 1,9 mg/1, 6.3 «mg/l and 4.1 mg/1, respectively, were found with the following respective day-
to-day coefficients of Variation: 12.3%, 5.2% and 5.3%. Amounts of prednisolone metabolites excreted in
the urine of these pätients were correlated with the ingested daily dose of prednisolone. It was concluded
that overall absorption of predaisolone in these pätients was adequate and not influenced by shortage of
bile acids in the gastro-intestinal tract, or by steatorrhoea, both caused by external bile drainage. In addition
there was no evidence for inereased metabolism of prednisolone.
*) Present Address: Liver Transplantation Surgery, Mayo Clinic, Rochester, MN, USA.
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Die Bestimmung von Prednisolon und einigen seiner MetaboUte im Harn zur Verlaufsbeobachtung der Predniso-
hn-Resorption bei Patienten nach orthotoper Lebertransplantation
Zusammenfassung: Bei Patienten mit orthotoper Lebertransplantation wurde Malabsorption bzw. erhöhter
Umsatz von Prednisolon vermutet. Zur Klärung wurden Prednisolon und einige seiner Metabohte (Prednison,
6ß-Hydroxyprednisolon) in Harn gaschromatographisch bestimmt. Zur Charakterisierung des Verfahrens
wurden 10-fach-Bestimmungen an einem gemischten Pool-Harn durchgeführt. Die Präzision von Tag zu Tag
betrug für Prednison (1,9 mg/1) 12,3%, für Prednisolon (6,3 mg/1) 5,2% und für 6 ß-Hydroxyprednisolon
(4,1 mg/1) 5,3%. Die Ausscheidung der Prednisolon-Metabolite wurde mit der aufgenommenen Dosis korre-
liert. Wir schließen, daß die Gesamt-Resorption von Prednisolon bei diesen Patienten angemessen und
unbeeinflußt (Verminderung der Gallensäuren im Gastrointestinaltrakt, Steatorrhoe infolge externer Gallen-
drainage) war. Es besteht kein Anhalt für einen gesteigerten Prednisolonumsatz.
Introduction
For the immunosuppressive regime after organ trans-
plantation there are in principle two choices: ciclo-
sporin/predniso(lo)ne and azathioprine/predniso-
(lo)ne. The liver transplantation group at Groningen
has so far used the combination azathioprine/predni-
solone in 48 orthotopic liver transplantations in 45
patients. Azathioprine does not influence the bio-
availability of prednisolone and thus these two drugs
can be used in combination (1).
Prednisolone is well absorbed from the gastro-intesti-
nal tract (2). Even after extensive small bowel resec-
tion, resulting in a jejunum length of 100 cm and a
jejunostomy, prednisolone was well resorbed (3).
Corticosteroids, such äs prednisolone, are eventually
excreted in the urine, together with their metabolites
(4). After a dose of 10 mg of prednisolone given to
6 healthy volunteers, between 11% and 19% of the
dose was excreted unmetabolised in the urine within
24 hours (5). After a dose of about 50 mg given to
5 healthy volunteers, between 21% and 33% was
recovered in the urine within 24 hours (6). The higher
percentage of excreted prednisolone can be ascribed
to a lower percentage of protein binding in serum,
when the concentration of the drug is increased.
Metabolites of prednisolone e. g. prednisone (6, 7),
6 ß-hydroxyprednisolone (6), 20 ß-hydroxypredniso-
lone (7) and 20 ß-hydroxyprednisone (7) are also ex-
creted in the urine. Neither biliary nor faecal excre-
tion is of any quantitative importance (4).
In some of our patients, who underwent liver trans-
plantation, malabsorption of prednisolone was
seriously considered on clinical grounds during episo-
des in the postoperative treatment. During the first
weeks after liver transplantation there is severe stea-
torrhoeä. This phenomenon is in part due to loss of
bile (including bile acids) via an external bile drai-
nage. Regarding prednisolone absorption and metab-
olism, it was of interest to enquire:
a) whether absorption is influenced by steatorrhoea
b) whether absorption is influenced by a shortage of
bile acids, and
c) whether liver transplantation affects the metab-
olism of prednisolone.
Our laboratory was asked to investigate prednisolone
absorption and metabolism in these patients. Predni-
solone resorption can be monitored by determining
its concentration in serum. However, this reqüires
protocolised serum sampling at regulär intervals dur-
ing the day. Therefore measurements of urinary ex-
creted prednisolone and prednisolone metabolites in
24 hour portions, which is easier to perform and
less troublesome to the patient, seems to be more
appropriate. In order to establish intra^individual
variances and variances due to malabsorption or to
decreased or increased metabolism of prednisolone,
we monitored urinary prednisolone and its metab-
olites in 10 orthotopic liver transplant patients* using
a gas Chromatographie procedure similar to that for
the determination of bile alcohols in urine (9). The
excreted amount of the bile alcohol 27-nor-5 ß-chole-
stane-3 ,7 , 12 a,24,25-pentol was also measured
within the same gas Chromatographie run. This bile
alcohol is endogenously synthesised in the liver and
thought to be a side product arising during biosyn-
thesis of cholic acid from cholesterol (10); the ex-
creted amount can therefore be used äs a parameter
of liver function (11 -^ 13), and in our particular case
äs an index of the postoperative recovery process. In
addition it can also be used äs a urine sampling
parameter; like creatinine, which is more commonly
measured äs a urine sampling parameter, 27-nor-S ß-
cholestane-3a,7<x,12a,24,25-pentol is apparently not
subject to strong fluctuations. The results obtained
in this study show that prednisolone absorption, even
during periods of steatorrhoea in orthotopic liver
transplanted patients, is not markedly disturbed. Fur-
thermore, there was no evidence for enhanced or
decreased metabolism of this drug.
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Materials and Methods
Materials
Sep-Pak C-18 cartridges were from Waters Ass. Inc. (Milford,
Ma, USA), prednisolone and prednisone were from Sigma
Chemical Company (St. Louis, Mo, USA), 6 ß-hydroxypredni-
solone and methyldeoxycholate (used äs internal Standard in
the gas Chromatographie assay) were from Steraloids Inc. (Wil-
ton, NH, USA), and Helix pomatia intestinal juice from Phar-
mindustrie (Clichy, France). A solution of 2% methoxamine-
HC1 in pyridine ('MOX') was from Pierce Chemical Co (Illinois,
USA). Trimethylbromosilane was purchased from Fluka AG
(Buchs, Switzerland). All other chemicals were of analytical
grade and purchased from Merck (Darmstadt, FRG). The fused
silica capiÜary column CP-Sil-5-CB, i.d. 0.20—0.22 mm, was
from Chrompack (Middelburg, The Netherlands).
Methods
Determinations of urinary prednisolone, prednisone and 6ß-hy-
droxyprednisolone
Prednisolone, prednisone, 6 ß-hydroxyprednisolone and 27-
nor-5 ß-cholestane-3 ,7 ,12 a,24,25-pentol were determined by
gas chromatography äs previously described for the determina-
tion of bile alcohols (9). The method was only slightly modified.
Depending on the expected concentration of prednisolone
metabolites, 0.2 to l ml of centrifuged urine was diluted with
distilled water to a volume of 2 ml. Sodium acetate buffer (pH
4.7, 5 mol/1) (100 ) and Helix pomatia juice (30 ) were
added. The mixture was incubated for 20 h at 37 °C. Then äs
internal Standard 50 of an ethanolic solution, containing 24.4
mg/1 methyldeoxycholate, was added and the mixture applied
to a Sep-Pak C18 cartridge, which was previously washed with
10 ml of methanol and 10 ml of distilled water, respectively.
After washing three times with 5ml of distilled water the
cartridge was eluted with two portions of 2 ml of methanol.
The eluate was evaporated to dryness at 60 °C unter N2. Deriva-
tisation to methoxime-trimethylsilyl derivatives was then per-
formed äs follows. Methoxamine solution (100 ) was added
and the solution heated for 3 h at 60 °C. The solvent was
evaporated at 60 °C under N2. A freshly prepared mixture of
bistrimethylsilylacetamide/trimethylbromo silane/pyridine
(4 + 1 + 5, v/v) (100 ) was added and the mixture 'allowed
to stand for 20 h at 4 °C. After the addition of 5 ml of hexane
and 5 ml of 0.1 mpl/1 HC1 solution, the product was purified
äs follows. The mixture was vortexed, then centrifuged, and
the aqueous layer was removed. Sodium hydroxide (l mol/1)
(2 ml), was added, followed by vortexing and centrifuging. The
aqueous layer was then removed and 3 ml of distilled water
was added. Following vortexing and centrifuging, the aqueous
layer was removed; the hexane layer was again washed with
3 ml of distilled water. After vortexing and centrifuging and
removal of the water layer, the hexane solution was evaporated
to dryness at 60 °C under nitrogen. After addition of 100 of
hexane 2 was introduced by splitiess injection inlo a Hewlett-
Packard 5880 A gas Chromatograph equipped with a split/
splitiess injection device for capillary columns and flame ionisa-
tion detection. Helium was used äs carrier gas with a flow rate
of l .5 ml/min. A 25-m fused silica CP-Sil-5-CB capillary column
was employed. Injector and detector temperature were 260 °C
and 290 °C respectively. Following injection the oven tempera-
ture was kept at 100 °C for 2minutes, then programmed at a
rate of 25 °C/minute to a temperature of 215°C and subse-
quently, at a rate of l .75 °C/minute to a final temperature of
295 °C. Quantification was done by comparison of peak areas
relative to that of the internal Standard (methyldeoxycholic
acid).
Determination offat infeces
Determinations of fat in feces were performed äs described
elsewhere (14).
Palients (tab. 1)
We studied 10 patients, 3 males and 7 females, median age 39
years (ränge 4—49). They were transplanted because of primary
biliary cirrhosis (5), chronic idiopathic cirrhosis (3), erythro-
poietic protoporphyria (1) and biliary atresia (1). Immune sup-
pression consisted of prednisolone and azathioprine. On the
day of Operation and the first two days after the Operation, 7 of
the 10 patients received additional methylprednisolone (1000 —
2500 mg). Methylprednisolone is also excreted in the urine,
partly äs such and also in the form of other metabolites;
although assay methods are available, we did not measure its
concentration. The observation period for this study was me-
dian 35 days (ränge 28 — 86) from the day of the orthotopic
liver transplantation.
Faecal fat excretion (g per day) was measured once a week.
Almost all patients had severe steatorrhoea during the whole
observation period; only three patients had periods with only
moderately increased faecal fat (5 —10 g per day). Bile loss via
external bile drainage lasted 22—70 days.
Samples
Urine samples were stored at —20 °C until analysis. A pooled
urine was made by mixing urine samples obtained from several
patients.
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Results
Gas Chromatographie peaks of methoxime-trimethyl-
silyl-derivatives of prednisolone and metabolites,
derived from the urine samples of our patients, were
identified by their retention times and mass spectra
(in comparison with the reference compounds). One
problem in the gas Chromatographie analysis of the
methoxime derivatives of steroids is that an oxo
group gives rise to two geometric isomers of the syn/
anti type (15). Therefore two peaks can arise from a
single substance (e.g. from prednisone or 6ß-hy-
droxyprednisolone). In the case of prednisolone,
however, these two peaks have nearly the same reten-
tion time. Therefore in the quantitative analysis of
prednisolone and its metabolites, peak areas includ-
ing the two isomers were determined relative to the
peak area of the internal Standard, and compared
with Standards.
Calibration curves for prednisone, prednisolone and
6 ß-hydroxyprednisolone, employing the area ratios
of the prednisone/internal Standard, prednisolone/
internal Standard and 6 ß-hydroxyprednisolone/inter-
nal Standard were all found to be linear in the ränge
0—20 g. The detection limit for all three substances
is about l ng. To evaluate the gas Chromatographie
assay we measured prednisone, prednisolone and 6 ß-
hydroxyprednisolone in multiplicate in a pooled ur-
ine. The day-to-day coefficients of Variation (n = 10)
and the corresponding mean values for prednisone,
prednisolone and 6 ß-hydroxyprednisolone were 1.9
mg/1, C.V. 12.3%, 6.3 mg/1, C.V. 5.2%, and 4.1 mg/1,
C.V. 5.3%, respectively. In addition, prednisone, pre-
dnisolone and 6 ß-hydroxyprednisolone were added
in varying amounts to aliquots of urine, in order to
determine recovery. For all three steroids this was in
the ränge of 90-110%.
After having established that determinations of uri-
nary prednisone, prednisolone and 6 ß-hydroxypred-
nisolone were reproducible and that the recovery of
added prednisone, prednisolone and 6 ß-hydroxy-
prednisolone was correct, urinary daily excretions of
prednisone, prednisolone, 6 ß-hydroxyprednisolone
and 27-nor-5 ß-cholestane-3 ,7 ,12 a,24,25-pentol
were determined and correlated with the ingested
daily dose. Figure l shows the ingested daily dose
of prednisolone and the excretions of prednisolone,
prednisone and 27-nor-5 ß-cholestane-3 ,7 ,
12 a,24,25-pentol in 24 hour urine portions of patients
A, B, C, D and E (fig. l a). In figure l b the same
data are supplemented with 24 hour excretions of
6 ß-hydroxyprednisolone in the remaining patients F,
G, H, J and K.
The daily excreted amounts of prednisolone and its
metabolites sometimes fluctuate strongly and unex-
pectedly. This phenomenon was usually observed in
the presence of conconiitant fluctuations in the ex-
creted amounts of the bile alcohol 27-nor-5-ß-chole-
stane-3 ,7 ,12 a,24,25-pentol, suggestingincorrect ur-
ine sampling äs mentioned in the^introduction. In
order to evaluate possible incorrect urine sampling
we compared the urinary daily excretions of 27-nor-
5 ß-cholestane-3 ,7 ,12 a,24,25-pentol and urinary
daily excretions of creatinine of patients B and F (fig,
2). Indeed strong fluctuations in creatinine values
accompany those of 27-nor-5 ß-cholestane-3 ,7 ,
12a,24,25-pentol confirming our supposition. Daily
urinary excretions of prednisolone by patients B and
F are also expressed äs g/mpl creatinine and g/g 27 ·̂
nor-5 ß-cholestane-3 a,7a,12a,24,25-pentol (fig. 2).
Representative steroid profiles of a patient who
underwent an orthotopic liver transplantation (3 A)
and another patient, not suffering from a liver disease
(B) are shown in figure 3. Both patients received an
oral dose of 60 mg of prednisolone per day. Figure 3
shows peaks of methyldeoxycholate (internal stan^
dard, peak 1), prednisone (peaks 2 A and 2 B), predni-
solone (peak 3), 20 ß-hydröxyprednisolone (peaks 4,
5, 7), 6 ß-hydroxyprednisolone (peaks 6, 8) and the
bile alcohol 27-nor-5 ß-cholestane-3 ,7 , 12 ,24,25-
pentol (peak 12). The mass spectrum of peak 9, which
is very similar to mass spectra retrieved from peaks
10 and 11, is presented in figure 4 and is presumably
that of a prednisolone inetabolite.
Discussion
In some patients, who had undergone orthotopic liver
transplantation, immunosüppression was thought to
be insufficient during certain episodes in the postop-
erative treatment. Therefore the clinicians asked our
laboratory to ascertain whether prednisolone was ad-
equately adsorbed. One way of showing this is to
measure the urinary excretion of unchanged predni-
solone and prednisolone metabolites in comparison
with normals. These measurements do not permit the
determination of the exact percentage of absorption,
but are sufficiently precise to establish whether or
not the greater part of this drug has been absorbed.
In addition they can show whether the metabolism
of the drug in our patients is different from normals.
Our study, performed on 10 orthotopic liver trans-
plant patients, shows that prednisolone absorption
and metabolism can be adequately monitored by
measuring the excretion of this drug and its metab-
J. Clin. Chem. Clin. Biochem. / Vol. 24,1986 / No. 11
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an orthotopic liver transplantation (A) and another
patient, not suffering from a liver disease (B); both
received an oral dose of 60 mg of prednisolone per day;
peak 1 = Internat Standard (methyldeoxycholate),
peak 2 = prednisone,
peak 3 = prednisolone,
peaks 4, 5, 7 = 20 -hydroxyprednisolone,
. peaks 6, 8 = 6 -hydroxyprednisolone,
;
^ peaks 9, 10, 1 1 are tentative identified s 6 ,20 -dihyd-
1 i roxyprednisolone and
N/A /\ 1̂  peak 12 = 27-nor-5 -cholestane-3a,7a,12a,24,25-pen-
• M/^
0 10 20 30 40 0 ~ 10 20 30 olites in 24 hour urine samples (see fig. 1). In theory
t [d ] nearly all the absorbed prednisolone should be re-
Fig. 2. Daily urinary excretion of 27-nor-5 -cholestane-
3a,7a,12a,24,25-pentol and creatinine, and urinary ex-
cretion of prednisolone expressed s mg/mg 27-nor-5 -
cholestane-3a,7a,12a,24,25-pentol and mg/mmol crea-
tinine of patients B and F.
covered in the urine, when the unaltered compound
together with all its metabolites are quantitatively
measured, because biliary and faecal excretion are
normally virtually absent (4). However a more practi-
cal approach is to measure only the urinary excretion
J. Clin. Chem..Clin. Biochem. / Vol. 24,1986 / No. 11













Fig. 4. Mass spectrum of the tentatively identified prednisolone metabolite:
6 ß,20 ß-dihydroxyprednisolone.
of prednisolone itself, since roughly about 25%, of
an ingested dose of 40 mg prednisolone or more per
day, is excreted unmetabolised. Such a percentage
was also found by others in 5 normal persons after
a dose of 50 mg (6). At lower doses of prednisolone
that percentage recovery of unchanged prednisolone
in the urine decreases, which is also in accordance
with other reports (5). Another conclusion to be
drawn from our measurements is that prednisolone
absorption in liver transplantated persons appears to
be practically complete in most cases, äs the excreted
amount closely foUows the ingested dose and ap-
proaches the above-mentioned 25%. Moreover the
metabolic profile is nearly identical with that of nor-
mal persons (see fig. 3), suggesting, that the metab-
olism of prednisolone is not fundamentally different.
As a consequence, the excretions of prednisolone
metabolites, such äs prednisone and 6 ß-hydroxypred-
nisolone, also correlates well with the ingested dose
of prednisolone. Even when a bile drain is present,
absorption continues to be optimal, which means that
bile acids do not play a role in the absorption process.
This observation is in accord with the fact that in
cholestyramine treated patients the absorption of
prednisolone remains undisturbed (16). In these
patients bile acids are almost absent within the
entero-hepatic cycle, äs these are bound to cholestyr-
amine (l gram of resin bounds about 2grams of
sodmm glycocholate (17)). In addition, the results
show that steatorrhoea has no influence on predniso-
lone resorption.
On certain days the excreted amount of prednisolone
and its metabolites seems to drop or rise considerably
(see for instance patient B (fig. l a) on the sixth day,
and patient F (fig. l b) on the twentysecönd day);
this phenomenon was usually also observed in the
concomitantly excreted amount of the bile alcohol
27-nor-5 ß-cholestane-3 a,7a,12a,24,25-pentol. How-
ever, the excreted amount of the latter substance
should be expected to drop or rise smoothly. There-
fore these two patients (B and F) were selected for a
comparison between the urinary excretions of 27-nor-
5 ß-cholestane-3 ,7 ,12 a,24,25-pentol and creatinine
(see fig. 2). This figure clearly shows that the excre-
tions of both substances are closely related to one
anöther and, in addition, that the unexpected de-
creases in the urinary excretion of the bile alcohol
also occur in the urinary excretion of creatinine.
Therefore in these instances, the 24 hour urine sam-
plings were not correctly perfonned, resulting in er-
roneous values. Correction for unreliable urine sam-
pling by giving the excreted amounts of urinary pred-
nisolone per mmol creatinine or per mg 27-nor-5 ß-
cholestane-3a,7a,12a,24,25-pentol is önly partly jus,
tified äs shown in figure 2. This is a consequence of
the fact that the urinary excretion of prednisolone
and metabolites, unlike that of creatinine and 27-nor-
5 ß-cholestane-3 a,7a,12a,24,25-pentol, is not con-
stant during the day, because the times of drug ad-
ministration are not evenly distributed throughout
the day. The rise of the prednisolone/27-nor-5 iß-
cholestaEne-3a,7a,12a,24,25-pentol ratio in urine in
J. Clin. Chem. Clin. Biochem. / Vol. 24,1986 / No. 11
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the latter stages of the post operative treatment is
explained by the fact that the 24 hour excretion
of the 27-nor-5ß-cholestane-3a,7a,12a,24,25-pentol
gradually drops after a successful Operation.
In addition to the known prednisolone metabolites,
mass spectrometric analysis of peaks 9, 10 and 11
(see fig. 4) revealed the existence of other metabolites
with nearly identical structures which, to our knowl-
edge, have not hitherto been described. The mass
spectrum, shown in figure 4, suggests the presence of
a dihydroxyprednisolone derivative, probably
6 ß,20 ß-dihydroxyprednisolone.
The mass fragments were assigned äs follows:
m/z 677 (M - 90)+, 587 (M - 2 90)+,
497 (M - 3 90)+, 407 (M - 4 90)+,
317 (M - 5 90)+
m/z 646 (M - 31 - 90)+
m/z 574 (M - 103 - 90)+,
484 (M - 103 - 2 90)+
m/z 562 (M - 205)+, 472 (M - 205 - 90)+,
382 (M - 205 - 2 90)+,
292 (M - 205 - 3 90)+
m/z 515 (M - 252)+, 425 (M - 252 - 90)+,
335 (M - 252 - 2 90)+
m/z 237 (C, - C6 + C10 + C19)+,
147 (d - C6 + C10 + C19 - 90)+
m/z 205 (C20 + C21)+, 115 (C20 -l· C2, - 90)+.
In conchision prednisolone absorption can conven-
iently be monitored by measuring the urinary excre-
tion öf prednisolone and its metabolites by capillary
gas liquid chromatography. The additional measure-
ments of 27-nor-5 ß-cholestane-3 a,7a,12a,24,25-pen-
tol provide a means of following the recovery process,
and, like the measurement of creatinine, provide a
Parameter for the correctness of the 24 hour urine
collection. Finally our study has provided evidence
that prednisolone absorption and metabolism in or-
thotopic liver transplant patients remains essentially
undisturbed, independent of external bile drainage or
steatorrhoea.
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